Coronary Artery Bypass (CAB) surgery is performed annually in >700,000 patients to treat coronary artery disease and prevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedure in arrested/non-beating heart, that is associated with long recovery times and severe complications. The surgeons are seeking for less invasive, closed chest CAB procedures on beating heart, but current solutions are technically extremely challenging and thereby only used in €89M and >€192M. Dutch SME AMT Medical has developed the proprietary SAFE-CAB technology to clinical readiness. To substantially accelerate the market entry of the product, the company partners with a leading European cardiac surgery hospital Deutsches Herzzentrum Berlin and a pan-European clinical/regulatory medical device company HEMEX to obtain regulatory approval through final clinical validation . To realize European wide-implementation, the consortium is complemented by a surgery training company LifeTec Group and the oldest professional organisation for cardiac surgeons European Society of CardioVascular and Endovascular Surgery.